Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 12:32 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 529–552 of 999 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Hemolysis Clear all
Recruiting Not applicable Interventional

School Readiness Intervention for Preschool Children With Sickle Cell Disease

NCT06367192
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
The adapted Kids in Transition to School Intervention, Standard school resources
Behavioral
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
42 Months to 78 Months
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 24, 2026 · Synced Oct 25, 2026, 12:32 PM EDT
Completed Not applicable Interventional

Sleep and Pain in Sickle Cell Disease

NCT03150433
View directory record Official record
Conditions
Sickle Cell Disease, Sleep Disturbance, Pain
Interventions
Behavioral symptom management, Sickle cell disease management
Behavioral · Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 100 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 24, 2025 · Synced Oct 25, 2026, 12:32 PM EDT
Completed Phase 2 Interventional Results available

Evaluating the Safety and Effectiveness of Decitabine in People With Thalassemia Intermedia

NCT00661726
View directory record Official record
Conditions
Thalassemia
Interventions
Decitabine (USAN, INN)
Drug
Lead sponsor
Carelon Research
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
2
States / cities
Oakland, California • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 25, 2014 · Synced Oct 25, 2026, 12:32 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Sickle Cell Kidney Biorepository

NCT07064174
View directory record Official record
Conditions
Sickle Cell Trait, Sickle Cell Disease (SCD), Chronic Kidney Disease
Interventions
Not listed
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
800 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2049
U.S. locations
2
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 25, 2026, 12:32 PM EDT
Terminated Phase 1 Interventional Results available

Safety Study of Gene Modified Donor T Cell Infusion After Stem Cell Transplant for Non-Malignant Diseases

NCT02231710
View directory record Official record
Conditions
Primary Immune Deficiency Disorders, Hemophagocytic Lymphohistiocytosis, Inherited Bone Marrow Failure Syndrome, Hemoglobinopathies, Metabolic Disorders
Interventions
BPX-501 and Rimiducid
Biological
Lead sponsor
Bellicum Pharmaceuticals
Industry
Eligibility
4 Months to 55 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 25, 2024 · Synced Oct 25, 2026, 12:32 PM EDT
Completed Phase 2 Interventional Results available

Phase II Randomized Trial:Arginine Butyrate Plus Standard Local Therapy in Patients With Refractory Sickle Cell Ulcers

NCT00004412
View directory record Official record
Conditions
Skin Ulcers, Sickle Cell Anemia
Interventions
Arginine Butyrate, Standard local care dressing
Drug · Other
Lead sponsor
Susan P. Perrine
Other
Eligibility
16 Years to 60 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2005
U.S. locations
4
States / cities
Chicago, Illinois • Boston, Massachusetts • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2015 · Synced Oct 25, 2026, 12:32 PM EDT
Recruiting Not applicable Interventional

Virtual Reality As Adjunct Therapy for Vaso-Occlusive Pain

NCT06773715
View directory record Official record
Conditions
Sickle Cell Disease, Vaso-occlusive Pain Episodes
Interventions
KindVR Aqua Program
Device
Lead sponsor
Louisiana State University Health Sciences Center in New Orleans
Other
Eligibility
8 Years to 21 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Jan 14, 2025 · Synced Oct 25, 2026, 12:32 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Sickle Cell Pro-Inflammatory Response to Interval Training Study

NCT03653676
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Exercise Test (CIIT)
Other
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
10 Years to 21 Years
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
3
States / cities
Chicago, Illinois • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 18, 2024 · Synced Oct 25, 2026, 12:32 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Multi-Center Study of Iron Overload: Pilot Study

NCT01114776
View directory record Official record
Conditions
Sickle Cell Disease, Thalassemia, Diamond-Blackfan Anemia
Interventions
Not listed
Lead sponsor
UCSF Benioff Children's Hospital Oakland
Other
Eligibility
16 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2013
U.S. locations
1
States / cities
Oakland, California
Source: ClinicalTrials.gov public record
Updated Sep 24, 2020 · Synced Oct 25, 2026, 12:32 PM EDT
Recruiting Phase 2 Interventional

Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-Thalassemia

NCT04143724
View directory record Official record
Conditions
Beta-Thalassemia
Interventions
ACE-536
Drug
Lead sponsor
Celgene
Industry
Eligibility
6 Years to 17 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2035
U.S. locations
2
States / cities
Los Angeles, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 25, 2026, 12:32 PM EDT
Terminated No phase listed Observational

Pyruvate Kinase (PK) Deficiency Global Longitudinal Registry: Patient-Reported Outcomes (PRO)

NCT04964323
View directory record Official record
Conditions
Pyruvate Kinase Deficiency, Pyruvate Kinase Deficiency Anemia, Anemia, Anemia, Hemolytic
Interventions
Not listed
Lead sponsor
Agios Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 7, 2023 · Synced Oct 25, 2026, 12:32 PM EDT
Recruiting Phase 2 Interventional

Haploidentical Donor Hematopoietic Cell Transplant for Sickle Cell Disease

NCT07616154
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Cyclophosphamide 50mg, Abatacept, Alemtuzumab, Hydroxyurea, Thiotepa, Filgrastim, Sirolimus, Azathioprine, TBI, Hematopoietic Progenitor Cell Infusion
Drug · Radiation · Procedure
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 22 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2035
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Oct 25, 2026, 12:32 PM EDT
Completed Phase 2 Interventional Results available

A Study to Determine the Efficacy and Safety of Luspatercept in Adults With Non Transfusion Dependent Beta (β)-Thalassemia

NCT03342404
View directory record Official record
Conditions
Thalassemia
Interventions
Luspatercept, Placebo, Best Supportive Care (BSC)
Drug · Other
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
4
States / cities
Los Angeles, California • Oakland, California • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 20, 2023 · Synced Oct 25, 2026, 12:32 PM EDT
Completed Phase 2 Interventional

Study of Deferasirox in Iron Overload From Beta-thalassemia Unable to be Treated With Deferoxamine or Chronic Anemias

NCT00061763
View directory record Official record
Conditions
Beta-thalassemia, Myelodysplastic Syndromes, Fanconi Syndrome, Anemia, Diamond-Blackfan, Anemia, Aplastic
Interventions
Deferasirox
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
2 Years and older
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
6
States / cities
Oakland, California • Stanford, California • Arlington Heights, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 22, 2017 · Synced Oct 25, 2026, 12:32 PM EDT
Recruiting Phase 1Phase 2 Interventional

T-Cell Depleted Alternative Donor Bone Marrow Transplant for Sickle Cell Disease (SCD) and Other Anemias

NCT03653338
View directory record Official record
Conditions
Sickle Cell Anemia, Beta-thalassemia Major, Diamond-blackfan Anemia
Interventions
CD3/CD19 depleted leukocytes, CD45RA depleted leukocytes, Hydroxyurea, Rituximab, Alemtuzumab, Fludarabine, Thiotepa
Biological · Drug
Lead sponsor
Paul Szabolcs
Other
Eligibility
5 Years to 40 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 25, 2026, 12:32 PM EDT
Completed No phase listed Observational

Evaluation of Toxicity From Stem Cell Transplant

NCT00631787
View directory record Official record
Conditions
Organ Dysfunction, Hemolysis
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
10 Years to 80 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 17, 2019 · Synced Oct 25, 2026, 12:32 PM EDT
Completed Phase 3 Interventional

Evaluation of Repeat Administration of Purified Poloxamer 188

NCT02449616
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
MST-188
Drug
Lead sponsor
Mast Therapeutics, Inc.
Industry
Eligibility
4 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2015
U.S. locations
9
States / cities
San Diego, California • Fort Myers, Florida • Hollywood, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2016 · Synced Oct 25, 2026, 12:32 PM EDT
Completed Not applicable Interventional Results available

SMYLS: A Self-management Program for Youth Living With Sickle Cell Disease

NCT04289311
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Voice Crisis Alert V2
Behavioral
Lead sponsor
Medical University of South Carolina
Other
Eligibility
11 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Aug 16, 2024 · Synced Oct 25, 2026, 12:32 PM EDT
Completed Not applicable Interventional

An mHealth Strategy to Improve Medication Adherence in Adolescents With Sickle Cell Disease

NCT04688411
View directory record Official record
Conditions
Sickle Cell Disease, Sickle Beta Zero Thalassemia, Sickle B+ Thalassemia, Sickle Cell Hemoglobin C
Interventions
MED-Go App
Behavioral
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
12 Years to 21 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 25, 2026, 12:32 PM EDT
Completed No phase listed Observational

Long Term Effects of Erythrocyte Lysis

NCT00842621
View directory record Official record
Conditions
Sickle Cell Disease, Hemolytic Anemia
Interventions
Clinical Evaluations, Laboratory Studies
Procedure · Other
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
5 Years and older
Enrollment
390 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 27, 2016 · Synced Oct 25, 2026, 12:32 PM EDT
Withdrawn Phase 2 Interventional

Study of Beet Juice for Patients With Sickle Cell Anemia

NCT02162225
View directory record Official record
Conditions
Sickle Cell Anemia
Interventions
beet juice (Unbeetable)
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
19 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 2, 2018 · Synced Oct 25, 2026, 12:32 PM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Relationship Between Abnormal Myocardial Perfusion and Diastolic Dysfunction in Sickle Cell Disease Using PET

NCT05583721
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
[13N]NH3, Lexiscan, Positron emission tomography
Drug · Diagnostic Test
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
18 Years to 21 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 25, 2026, 12:32 PM EDT
Active, not recruiting Phase 2 Interventional

A Gene Transfer Study Inducing Fetal Hemoglobin in Sickle Cell Disease (GRASP, BMT CTN 2001)

NCT05353647
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Autologous CD34+ HSC cells transduced with the lentiviral vector containing a shRNA targeting BCL11a
Biological
Lead sponsor
David Williams
Other
Eligibility
13 Years to 40 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
9
States / cities
Los Angeles, California • Oakland, California • Sacramento, California + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 25, 2026, 12:32 PM EDT
Not listed No phase listed Observational

STRIDE Biorepository

NCT02843347
View directory record Official record
Conditions
Anemia, Sickle Cell
Interventions
Blood draw
Procedure
Lead sponsor
Emory University
Other
Eligibility
15 Years to 40 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
40
States / cities
Oakland, California • Washington D.C., District of Columbia • Gainesville, Florida + 28 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2021 · Synced Oct 25, 2026, 12:32 PM EDT